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This study explores demographic, clinical, and therapeutic features of tumor necrosis factor receptor-associated periodic syndrome
(TRAPS) in a cohort of 80 patients recruited from 19 Italian referral Centers. Patients’ data were collected retrospectively and then
analyzed according to age groups (disease onset before or after 16 years) and genotype (high penetrance (HP) and low penetrance
(LP) TNFRSF1A gene variants). Pediatric- and adult-onset were reported, respectively, in 44 and 36 patients; HP and LP variants
were found, respectively, in 32 and 44 cases. A positive family history for recurrent fever was reported more frequently in the
pediatric group than in the adult group (p < 0:05). With reference to clinical features during attacks, pericarditis and myalgia
were reported more frequently in the context of adult-onset disease than in the pediatric age (with p < 0:01 and p < 0:05,
respectively), while abdominal pain was present in 84% of children and in 25% of adults (p < 0:01). Abdominal pain was
significantly associated also to the presence of HP mutations (p < 0:01), while oral aphthosis was more frequently found in the
LP variant group (p < 0:05). Systemic amyloidosis occurred in 25% of subjects carrying HP variants. As concerns laboratory
features, HP mutations were significantly associated to higher ESR values (p < 0:01) and to the persistence of steadily elevated
inflammatory markers during asymptomatic periods (p < 0:05). The presence of mutations involving a cysteine residue,
abdominal pain, and lymphadenopathy during flares significantly correlated with the risk of developing amyloidosis and renal
impairment. Conversely, the administration of colchicine negatively correlated to the development of pathologic proteinuria
(p < 0:05). Both NSAIDs and colchicine were used as monotherapy more frequently in the LP group compared to the HP group
(p < 0:01). Biologic agents were prescribed to 49 (61%) patients; R92Q subjects were more frequently on NSAIDs monotherapy
than other patients (p < 0:01); nevertheless, they required biologic therapy in 53.1% of cases. At disease onset, the latest
classification criteria for TRAPS were fulfilled by 64/80 (80%) patients (clinical plus genetic items) and 46/80 (57.5%) patients
(clinical items only). No statistically significant differences were found in the sensitivity of the classification criteria according to
age at onset and according to genotype (p < 0:05). This study describes one of the widest cohorts of TRAPS patients in the
literature, suggesting that the clinical expression of this syndrome is more influenced by the penetrance of the mutation rather
than by the age at onset itself. Given the high phenotypic heterogeneity of the disease, a definite diagnosis should rely on both
accurate working clinical assessment and complementary genotype.
1. Background
Tumor necrosis factor receptor-associated periodic syndrome
(TRAPS) is one of the most common autosomal dominant
autoinflammatory diseases and is caused by mutations in
the tumor necrosis factor receptor super family member
1A (TNFRSF1A) gene on chromosome 12p13. Originally
identified in northern Europe and French-Canadian ancestry
families during the last decades of the XX century, it has
been recognized thereafter mainly in Caucasians, but also in
patients from Africa and Asia, with an estimated prevalence
of about one per million people [1]. The incidence of TRAPS
is very low; it has been calculated as 5.6 cases per 107 person-
years for the period 2003–06 in German children, which corre-
sponds to 6–10 newly diagnosed young patients per year [2].
Nevertheless, like other rare conditions, this multifaceted dis-
ease is potentially both underdiagnosed and underreported.
Among the expanding spectrum of hereditary recurrent
fevers, TRAPS remains one of the most variable as concerns
clinical features, age at onset, and disease severity, ranging from
the mildest phenotype often associated to low-penetrance (LP)
genetic variants to a severely disabling condition in patients
carrying structural high-penetrance (HP) variants; in the latter
group, systemic amyloidosis represents the most threatening
complication of the syndrome, affecting 10-15% of untreated
subjects [3, 4]. Patients may display a relapsing-remitting
course, with prolonged high-grade fever attacks accompanied
by a systemic inflammatory reaction and localized flogosis of
any potential site, with skin, muscles, abdomen, eye, joints,
serousmembranes, and lymphnodes being themost frequently
targeted [5]. Otherwise, patients may exhibit a chronic course,
characterized by symptomatic intervals between fever attacks
and/or inflammatory markers steadily elevated.
Actually, neither functional tests nor diagnostic criteria
are available to identify the disease in the clinical setting,
and TRAPS diagnosis relies on the detection of a pathogenic
variant of the TNFRSF1A gene. Currently, more than 160
gene mutations have been found, and 99 of them are classi-
fied as pathogenic or likely pathogenic, according to Infevers
database (Infevers: an online database for autoinflammatory
mutations. Copyright. Available at https://infevers.umai-
montpellier.fr/ Accessed 2019.12.22) [6]. The majority of
these disease-associated mutations are identified in exons 2,
3, and 4, encoding the extracellular domain of TNF receptor.
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The uncertainty regarding the pathogenic role of some LP
mutations, such as R92Q and P46L, whose estimated allele
frequency is 10% and 2% in West African and Caucasian
population, respectively, further complicates the diagnostic
challenge, since many carriers do not manifest any symptom,
while other ones develop a mild-moderate phenotype with
specific clinical features [7, 8]. Classification criteria for
TRAPS have been recently developed and validated on the
basis of Eurofever Registry by the Paediatric Rheumatology
International Trials Organisation (PRINTO) [9]. Moreover,
specific clinimetric tools have been recently proposed to assess
disease activity and disease-induced systemic organ damage.
In particular, the autoinflammatory disease activity index
(AIDAI) is used in clinical practice for measuring disease
activity during a 1-month period according to the presence
or absence of selected inflammatory manifestations reported
day by day [10]; the autoinflammatory disease damage index
(ADDI) is used to establish chronic organ damage owing to
disease activity over time [11].
Few studies in the literature compared clinical features
according to the age of disease onset [1, 3, 12], and no data
at all are available about the performance of the new TRAPS
classification score in different age groups and compared to
the preexisting Eurofever score [13]. This multicenter study
was designed to define demographic, clinical, and therapeutic
features of a large cohort of TRAPS patients in Italy, distin-
guished according to different age at onset and genetic vari-
ants, on the basis of the nation-wide collaborative experience
of the Autoinflammatory Disease Alliance (AIDA) Network
and the Working Group for Autoinflammatory Disease of
the Italian Society of Rheumatology.
2. Patients and Methods
This retrospective observational multicenter study recruited
80 patients from nineteen Italian rheumatology and pediatric
rheumatology tertiary referral Centers participating to the
AIDA Network and to the Working Group for Autoinflam-
matory Disease of the Italian Society of Rheumatology.
Patients were included in the study if TRAPS was diagnosed
by the referring physician on the basis of consistent clinical
history and genotype. A structured form was sent to local
investigators, collecting demographic, clinical, therapeutic,
and clinimetric data from clinical charts. Provisional Eurof-
ever score for TRAPS according to Federici et al. [13] was
calculated for every patient by the referring physician;
classification scores for TRAPS, FMF, mevalonate kinase
deficiency (MKD), and cryopyrin-associated periodic syn-
dromes (CAPS) were subsequently derived by the authors
on the basis of available data, according to Gattorno et al. [9].
According to criteria used in previous studies, patients
aged <16 and ≥16 years at disease onset were considered
to have pediatric and adult disease onset, respectively
[2, 3, 14, 15]. In order to distinguish patients according to
genotype, we divided the cohort into two main groups:
patients carrying TNFRSF1A HP mutations (HP group)
and patients carrying TNFRSF1A LP mutations (LP group).
Three patients with a convincing clinical phenotype had
no mutations detected using Sanger sequencing; however,
somatic mosaicism could not be formally excluded at the
time of enrolment. These patients, along with a fourth
patient carrying a mutation with unknown penetrance, were
excluded when the statistical analysis was performed to
assess features according to genetic groups. Phenotypical
characteristics of specific genetic subgroups (R92Q; muta-
tions involving a cysteine residue; HP mutations not involv-
ing cysteine residues) were also explored.
Regarding response to treatment, “complete response”was
defined as complete control of clinical and laboratorymanifes-
tations; “partial response” was meant as: (i) a decrease in
clinical severity of flares corresponding to a less severe
systemic inflammation during disease attacks; (ii) a patient-
reported improvement in clinical manifestations during flares
for relapsing-remitting disease courses or outside of flares for
chronic cases. The response of patients not meeting these
criteria was defined as “complete inefficacy”.
The study protocol was conformed to the tenets of the
Declaration of Helsinki and was approved by the local Ethics
Committee of the University of Siena (Reference No.14951).
Written informed consent for using clinical data for research
purposes was obtained according to the local Institutional
review board guidelines.
2.1. Aims of the Study. The primary aim of the study was to
describe demographic, clinical, and therapeutic features of
TRAPS according to age at disease onset in a large cohort
of patients.
Secondary aims were (I) to describe demographic, clinical
and therapeutic features of TRAPS according to the pene-
trance of TNFRSF1A variants (HP variants group versus LP
variants group) and specific genotype subgroups (R92Q; HP
mutations involving a cysteine residue; HP mutations not
involving cysteine residues); (II) to evaluate how TRAPS
classification criteria [9, 13] work across different age and
genetic groups; (III) to explore any associations between
clinical/laboratory features of the whole cohort of patients at
disease onset and prognostic indicators including the occur-
rence of systemic amyloidosis at the time of diagnosis and
pathologic proteinuria.
2.2. Statistical Analysis. Data were analyzed using IBM SPSS
Statistics. Descriptive statistics included sample sizes, mean
and standard deviation (SD), or median and interquartile
range (IQR), as appropriate. Shapiro–Wilk test was used
to assess the normality distribution of data. Categorical
variables were analyzed using 2 × 2 contingency tables with
Fisher’s exact test, while analysis of means was investigated
through Mann–Whitney U test or unpaired samples T-test,
as appropriate. Correlations between clinical features and
prognostic indicators were performed employing Kendall’s
tau-b test. Binary logistic regression was performed to detect
potential factors predictive of the development of amyloid-
osis or pathologic proteinuria. Logistic or nominal regres-
sion was applied to find any impact of the treatment
duration with biologic agents or the duration of follow-up
at the last visit on the following outcomes: discontinuation
of biologic therapy, dose adjustments of biologic agents,
occurrence of adverse events during biologic treatment,
3Mediators of Inflammation
and the ADDI score recorded at the end of follow-up. The
threshold for statistical significance was set to p < 0:05,
and all p values were two-sided.
3. Results
3.1. Demographic and Genotypical Characteristics. Demo-
graphic characteristics of TRAPS patients in the whole cohort
and in different age at onset and genetic groups are summa-
rized in Table 1. Caucasian ethnicity was the most represented
(92.5%), while Arabic, Afro-American, and Jewish ethnicities
accounted for 2.5%, 2.5%, and 1.3%, respectively. Forty-four
individuals (55%) had pediatric-onset disease and 36 (45%)
had adult-onset disease. Mean diagnostic delay was 23:4 ± 16
years (range 1.0-44.0) in the pediatric-onset group and
15:6 ± 11:6 years (range 2.0-31.0) in the adult-onset group
(p < 0:001). Mean disease duration at last follow-up visit
was 33.8 years in the pediatric-onset group and 14.2 years
in the adult-onset group (p = 0:002).
Details about the genotypical characterization of the
cohort are summarized in Figure 1 and Table 2. In particular,
TNFRSF1A HP mutations were detected in 32 patients (40%)
and LP mutations in 44 patients (55%). The median age at
onset was 5.0 (IQR = 14:1) years (range 1.0-49.0) among HP
carriers and 16.0 (IQR = 26:5) years (range 1.0-48.0) among
LP carriers, with p = 0:01. In the HP group, pediatric-onset
disease occurred in 94% of cases among patients carrying cys-
teine substitutions and in 56% of cases among patients with
HP mutations not involving cysteine residues (p = 0:01).
Median diagnostic delay was significantly longer in the group
of patients carrying TNFRSF1A HP mutations (30.0 years,
IQR = 26:0; min 1.0, max 60.0) than in the LP group (7.0
years, IQR = 15:0; min 1.0, max 47.0) with p < 0:001. No
statistically significant differences were found as concerns
ethnicity and sex predominance.
3.2. Clinical Features at Disease Onset. A familial history of
recurrent fever was present in about 38% of cases. The
disease displayed a relapsing-remitting course in 59 patients
(74%) and a chronic course in 21 cases (26%). Before starting
biologic therapy 43% of patients had 2-6 attacks per year,
34% had 6-12 attacks per year, 15% more than 12 attacks
per year; 8% of subjects had less than 2 attacks per year.
The mean duration of fever attacks was 13 days, ranging from
1.5 to 30 days. Musculoskeletal symptoms were the most
common clinical features accompanying fever: arthralgia
and myalgia were reported in 70% and 66% of patients,
respectively, while arthritis was less common (34%). Abdom-
inal pain and chest pain were presented by 58% and 34% of
individuals. Other common clinical features were skin rash
in 41% of cases (urticarial in 27.5%, erythematous in 6.3%,
maculopapular in 5%, erythema nodosum in 2.5% and
petechial rash in 1.3% of the cohort) and lymph nodes
enlargement in 38% of cases, while other manifestations were
less frequently reported (pharyngitis 30%, oral aphthosis
25%, pericarditis 22.5%, fatigue 18.8%, conjunctivitis 17.5%,
periorbital edema 17.5%, liver and/or spleen enlargement
11.3%, pleurisy 10%, headache 10%, diarrhea 3.8%, vomiting
2.5%, tinnitus 1.3% and scleritis 1.3%). In detail, pericarditis
was reported in 18 patients, with a mean age at disease onset
of 29 years (range 4-59 years). In 6 cases, a concurrent
involvement of the pleural serosa was detected; moreover,
arthralgia, myalgia, and arthritis were the most frequent
accompanying manifestations (in 14, 10, and 8 out of 18
patients, respectively). Systemic amyloidosis and pathologic
proteinuria were present, respectively, in 8 and 9 patients
out of 80 at diagnosis.
Table 1: Demographic characteristics of TRAPS patients described in the whole cohort of the study, according to age at onset and according
to the penetrance of TNFRSF1A mutations. List of abbreviations: IQR: interquartile range; N.: number of patients; n.s.: not significant;














Numerosity N. (%) 80 (100%) 44 (55%) 36 (45%) 32 (40%) 44 (55%)
Male : female 42 : 38 26 : 18 16 : 20 n.s. 19 : 13 20 : 24 n.s.
Age at recruitment, years
Median (IQR) or mean ± SD 44.0 (31.0) 41:7 ± 19:8 40:4 ± 15:8 n.s. 48:7 ± 18:1 38:8 ± 16:5 0.04
Age at onset, years
Median (IQR) or mean ± SD 8.0 (16.2) 4:9 ± 2:5 19:4 ± 2:5 <0.001 5.0 (14.1) 16.0 (26.5) 0.01
Age at diagnosis, years
Mean ± SD 32:9 ± 15:9 28:3 ± 16:4 35:0 ± 13:7 0.003 39:6 ± 17:0 30:3 ± 14:5 0.01
Diagnostic delay, years
Median (IQR) or mean ± SD 18.0 (27.5) 23:4 ± 16:0 15:6 ± 11:6 <0.001 30.0 (26.0) 7.0 (15.0) <0.001
Duration of disease at last
visit, years
Median (IQR) or mean ± SD
26.0 (36.5) 33:8 ± 19:8 14:2 ± 10:3 0.002 35.5 (27.3) 12.0 (20.5) 0.002
Follow-up duration, years
Median (IQR)
6.0 (8.0) 9.0 (8.5) 5.0 (14.0) n.s. 8.0 (6.4) 5.0 (9.5) n.s.
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Figure 2 displays the clinical characteristics of TRAPS
patients at disease onset, according to age at onset. A familial
history of recurrent fever was present in 52% of pediatric-
onset cases and in 22% of adult-onset cases (p = 0:02).
Among clinical features during attacks, pericarditis and
myalgia were reported more frequently in the context of
adult-onset disease than in the pediatric age (with p = 0:008
and p = 0:04, respectively) while abdominal pain was present
in 84% of children and in 25% of adults (p < 0:001). No other
statistically significant differences were found between the
two groups as concerns clinical presentation and laboratory
markers, namely mean C-reactive protein (CRP) and eryth-
rocyte sedimentation rate (ESR) measured during fever
attacks and mean serum amyloid A protein (SAA) and mean
24-hours proteinuria measured outside of fever episodes.
Figure 3 displays the clinical characteristics of TRAPS
patients at disease onset, according to the penetrance of
TNFRSF1A mutations. Subjects carrying HP mutations had a
consistent familial history in 56% of cases, while in the LP
group the frequency was 25% (p = 0:04). Regarding clinical
manifestations, abdominal pain was significantly more
frequent in patients with HP mutations (84% versus 36%, p
< 0:001), while oral aphthosis was more frequently reported
in the LP variant group (32% versus 9%, p = 0:02). Moreover,
among HP variants group, lymphadenopathy was significantly
more frequent in the non-cysteine group than in the cysteine
group (p = 0:02). The difference in the occurrence of systemic
amyloidosis between the two groups was highly significant
(25% of HP variants patients versus 0% of LP variants patients,
p = 0:002). As concerns laboratory features, patients with HP
mutations had higher ESR than that observed in LP group
(86:6 ± 37:4 versus 60:0 ± 27:2mm/h, p = 0:003); inflamma-
tory markers steadily increased during intervals between
attacks were more commonly found in the HP than in the
LP variants group (28% and 9% of cases respectively, p = 0:04).
3.3. Clinimetrics and Classification Criteria. At disease onset,
median AIDAI and ADDI scores were 10 (IQR = 13) (min. 0;
max. 120) and 1 (IQR = 2) (min. 0; max. 12), respectively,
with no statistically significant difference between groups.
AIDAI score at the start of biologic therapy was stable in
33% of patients, increased in 9% of patients, and decreased
in 16% of cases, without any significant difference between
groups. AIDAI score decreased after 3, 6, and 12 months
since the start of biologic therapy and at last follow-up visit
in 95.5%, 88.1%, 92.5%, and 88.4% of patients, respectively.
The edition of the Eurofever score by Federici et al. [13]
was fulfilled by 57/80 patients (71.3%). The difference between
the sensitivity of the score in the HP variant group (93.8%)
and in the LP variant group (56.8%) was highly significant
(p < 0:001). The latest TRAPS classification criteria proposed
by Gattorno et al. for patients carrying TNFRSF1A gene
variants [9] were satisfied at disease onset by 64 out of 80
patients (80%); TRAPS classification criteria purely based on
clinical features (and no reference to genetic findings) [9] were
fulfilled by 46 out of 80 patients (57.5%). No statistically
significant differences were found in the sensitivity of the
classification criteria according to age at onset and according
to genotype, as displayed in Table 3 along with percentages
of the fulfillment of the two different editions of the Eurof-
ever scores.
3.4. Prognostic Data.As concerns prognostic data, mutations
involving a cysteine residue and the presence of abdominal
pain during attacks at disease onset significantly correlated
with the development of pathologic proteinuria (p = 0:001
and p = 0:04, respectively); lymphadenopathy during attacks
significantly correlated with the development of amyloidosis
(p = 0:018); the discontinuation of biologic treatment
because of secondary inefficacy was significantly correlated
with the development of amyloidosis and pathologic-
proteinuria (p = 0:03 in both cases), while the use of colchi-
cine was negatively correlated with the development of
pathologic proteinuria (p = 0:03). No other significant corre-
lations were found between other clinical, laboratory and
therapeutic data, and prognostic measures. Binary logistic
regression detected lymphadenopathy during febrile epi-
sodes as the only variable associated with the development
of amyloidosis (OR = 6:14 [1.14-33.07], p = 0:04), and the
presence of mutations affecting cysteine residues as the only
variable associated with the development of pathologic
proteinuria (OR = 6:82 [1.58-29.46], p = 0:01).
3.5. Characteristics of Patients Carrying R92Q Variant. The
distribution of clinical manifestations across the R92Q
mutation group (n = 32) is displayed in Figure 4. They had
a median age at onset of 5 (IQR = 15) years, with disease
onset occurring in the pediatric age and in the adult age in
41% and 59% of cases, respectively. The mean duration of
attacks was 12 days, and 55% of patients had more than 6
attacks per year. Oral aphthosis and arthritis were more
frequently reported among R92Q patients (p = 0:04 in both
cases), while abdominal pain was less commonly experienced
(p = 0:001), and no cases of amyloidosis were reported at all
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Figure 1: Genotypical characterization of TRAPS patients.
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Table 2: Genotypical characterisation of TRAPS patients. List of abbreviations: TNFRSF1A: tumor necrosis factor receptor super family
member 1 A; HGVS: Human Genome Variation Society.
TNFRSF1A mutation(s)
Frequency
HGVS sequence name HGVS protein name Usual name
Low penetrance
c.123T>G p.(Asp41Glu) D12E 3
c.143A>T p.(Lys48Ile) — 1
c.224C>T p.(Pro75Leu) P46L 5
c.362G>A p.(Arg121Gln) R92Q 32
c.370G>A p.(Val124Met) V95M 1
c.398G>A p.(Arg133Gln) R104Q 2
Unknown penetrance
c.1181G>A p.(Arg394His) — 1
Others 3
High penetrance
c.214T>C p.(Cys72Arg) C43R 2
c.215G>A p.(Cys72Tyr) C43Y 1
c.236C>T p.(Thr79Met) T50M 10
c.242G>A p.(Cys81Tyr) C52Y 3
c.244A>G p.(Arg82Gly) R53G 2
c.251G>A p.(Cys84Tyr) C55Y 1
c.262T>C p.(Ser88Pro) S59P 2
c.305G>A p.(Cys102Tyr) C73Y 2
c.349T>G p.(Cys117Gly) C88G 1
c.373T>C p.(Cys125Arg) C96R 3
c.380G>T p.(Cys127Phe) — 1
c.394_399del p.(Tyr132_Arg133del) Y103_R104DEL 1
c.472+1G>A p.(Cys158delinsYERSSPEAKPSPHPRG) c.472+1G>A 2





























Figure 2: Clinical characteristics of TRAPS patients at disease onset, according to age at onset.
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lower than ESR recorded among patients with different
mutations (49 versus 74mm/h, p = 0:007). The last Eurofever
TRAPS classification criteria were met in 53.3% (17/32) of
cases when only clinical features were included and 81.3%
(26/32 patients) when considering genotype. R92Q patients
were more frequently on nonsteroidal anti-inflammatory
drugs (NSAIDs) monotherapy than other patients (78.1%
versus 37.5% of cases, p < 0:001); biologic therapy was
administered in 53.1% of cases (13 anakinra, 2 canakinumab,
2 etanercept).
3.6. Therapeutic Data. Regarding treatment, NSAIDs have
been administered as monotherapy in about half of TRAPS
patients (53.8%), on a daily regimen (17.5%), on demand
(27.5%), or with unknown regimen (8.8%). About 16% of them
reported complete response to NSAIDs, 58% partial response,
19% complete inefficacy, 7% unknown response. NSAIDs were
used as monotherapy more frequently in the group of adult-
onset disease than in the group of pediatric-onset (64% versus
46%, p < 0:001), and more frequently in the LP mutations
group compared to the HP variants group (71% versus 31%,
p = 0:001). There were no significant differences between
groups as concerns therapeutic regimens and clinical response
to NSAIDs.
Glucocorticoids (GC) were administered as monotherapy
in 60 TRAPS patients (75%), on a daily regimen (36.3%), on
demand (32.5%), or with unknown regimen (6.3%). Daily
dose ranged from 5 to 150mg/day (mean dose = 35mg/day)
and from 0.6 to 2.5mg/kg/day (mean dose = 1:2mg/kg/day).
Complete response to CS as monotherapy was reported by
53% of patients, partial response in 28% and complete
inefficacy in 12% (data not available in 7% of cases). There
were no statistical differences between groups as concerns
therapeutic regimen and clinical response to GC.
Colchicine was administered as monotherapy in 31
TRAPS patients (38.8%). About 10% of them reported
complete response to colchicine, 45% partial response, 23%
complete inefficacy (data not available in 22% of cases).
Colchicine was used as monotherapy more frequently in
the LP mutations group compared to the HP variants group
(50% versus 25%, p = 0:002). There were no other significant
differences between groups as concerns employment and
clinical response to colchicine.
Biologic agents were prescribed to 49 (61%) patients. In
detail, any biologic course was prescribed to 20 (56%)
patients of the adult-onset group, 29 (66%) patients of the
pediatric-onset group, 23 (72%) of the HP group, and 24
(55%) of the LP group. No statistically significant differences
emerged between groups about the frequency of biological
therapy administration. Interleukin-1 (IL-1) inhibitors were
chosen as first-line biologic agent in 86% of cases (anakinra
in 28 subjects, canakinumab in 14 subjects); the remaining
patients were treated with a TNF inhibitor as first-line bio-
logic drug (adalimumab, infliximab and etanercept in 1, 1
and 5 cases, respectively). The majority of patients were ini-
tially treated with standard posology (88%), while the initial
dose of the biologic agent was higher in 4 cases—treated with
anakinra (1), canakinumab (2), or adalimumab (1)—and
lower in 1 case undergoing anakinra. In 18 (37%) cases, the
initial posology was adjusted during follow-up, by increasing
or decreasing the dose (in 2 and 4 cases, respectively) or by
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Figure 3: Clinical characteristics of TRAPS patients at disease onset, according to the penetrance of TNFRSF1A mutations.
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(in 2 and 10 cases, respectively). Mean disease duration at the
start of biologic therapy was 20 years (min. 1; max. 65), and
the mean duration of biologic therapy was 38 months (min.
1; max. 120). About 73% of patients reported complete
response to biologic agents, 12% partial response, and 6%
complete inefficacy (data not available in 9% of cases). Fifteen
Table 3: Fulfillment of TRAPS Eurofever score according to Federici et al.. 2015 [13] (“TRAPS Eurofever score 2015”) and classification
criteria according to Gattorno et al.. 2019 [9] (“genetic + clinical classificative criteria 2019” and “clinical classificative criteria 2019”) in
the whole cohort of TRAPS patients and according to age at onset and TNFRSF1A mutations penetrance. List of abbreviations: CAPS:
cryopyrin-associated periodic syndrome; FMF: familial Mediterranean fever; MKD: mevalonate kinases deficiency; n.a.: not available; n.s.:



















TRAPS Eurofever score 2015 (%) 71.3 75.0 66.7 n.s. 93.8 56.8 <0.001
TRAPS genetic + clinical classificative criteria
2019 (%)
80.0 84.1 75.0 n.s. 93.8 77.3 n.s.
TRAPS clinical classificative criteria 2019 (%) 57.5 61.4 55.9 n.s. 71.9 50.0 n.s.
Fever ≥7days (%) 78.8 84.0 72.2 n.s. 87.5 79.5 n.s.
Fever 5–6 days (%) 8.8 13.6 2.8 n.s. 6.3 11.4 n.s.
Migratory rash (%) 6.3 4.5 8.3 n.s. 6.3 6.8 n.s.
Periorbital oedema (%) 17.5 22.7 11.1 n.s. 15.6 15.9 n.s.
Myalgia (%) 66.3 56.8 77.7 n.s. 56.3 72.7 n.s.
Positive family history (%) 38.8 52.3 22.2 0.01 56.3 25.0 0.01
Absence of aphthous
stomatitis (%)
75.0 72.7 77.7 n.s. 90.6 68.2 0.02
Absence of
pharyngotonsillitis (%)
70.0 65.9 75.0 n.s. 81.3 68.2 n.s.
FMF clinical classificative criteria 2019 (%) 12.5 4.5 23.5 0.01 12.5 11.9 n.s.
MKD clinical classificative criteria 2019 (%) 12.5 20.5 2.9 0.02 6.3 14.3 n.s.
CAPS clinical classificative criteria 2019 (%) 0 0 0 n.a. 0 0 n.a.
No clinical classificative criteria 2019 (%) 25 25 26.5 n.s. 15.6 33.3 n.s.




























Figure 4: Clinical characteristics of patients carrying R92Q variant at disease onset, compared with patients carrying other TNFRSF1A variants.
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(31%) subjects discontinued the therapy due to primary
inefficacy (n = 3, 6%), secondary inefficacy (n = 7, 14%),
adverse events (n = 2, 4%), lack of compliance (n = 2, 4%),
or other reasons (n = 5, 10%). Eight patients manifested
adverse events during biologic treatment (16%): 3 subjects
had injection site reactions to anakinra, 1 had chest pain
and 1 amnesia with anakinra, 1 subject had recurrent low
urinary tract infections and 1 varicella-zoster virus infection
with canakinumab, and 1 subject had a paradoxical inflam-
matory reaction to infliximab.
Logistic regression analysis did not find any relation
between the duration of biologic therapy or the duration of
follow-up and discontinuation of therapy, dose adjustments,
and occurrence of adverse events.
The frequency of therapeutic regimens in TRAPS patients,
according to age at onset and genotype is displayed in Figure 5.
4. Discussion
The present study outlines the characteristics of a large
cohort of TRAPS patients resulting from a positive nation-
wide collaborative research experience in the field of autoin-
flammatory diseases. The size of this series gave us the oppor-
tunity to explore how this extremely rare disease shows up to
the attention of both pediatric and adult services, a matter of
the utmost relevance since the diagnosis of TRAPS relies on
the detection of a confirmative mutation in the causative
gene through specific tests of limited availability and signifi-
cant expense.
Although disease onset is known to occur usually around
the age of four, a significant variability emerges from the
literature, ranging from the first weeks of life to the sixties
[16–18]. In our cohort, the median age at onset was eight
years, but disease presented itself in adulthood in almost half
of patients (range 1-59 years). The evidence that an earlier
onset of symptoms is accompanied by the detection of HP
gene variants is well known in the literature [7, 8], and this
data is further validated in this series; interestingly, we found
that mutations involving cysteine residues accounted for the
earlier onset in the HP variant group (94% pediatric-onset),
while patients with HP mutations not involving cysteine
residues (T50M, S59P, c.472+1G>A, R53G, c.586_612del27,
and Y103_R104DEL) had pediatric-onset only in 56% of
cases. Data previously reported from the Eurofever registry
showed that adult patients with disease onset in childhood
carried a single variant involving T50M or a cysteine residue
in 51% of cases, while patients with an adult-onset carried
them in 23% of cases, and the difference was statistically
significant [1]. Papa et al. reported a mean age at onset of
9.4 years in patients carrying T50M, S59P, or del130-104 var-
iants and a mean age at onset of 2.6 years in patients carrying
the cysteine mutations C43R, C43Y, C52Y, and C55Y [17].
Such early onset disease may be explained by the crucial role
of the cysteine-rich domains for the preservation of the three-
dimensional conformation of the extracellular part of the
TNF receptor, which relies on the presence of intramolecular
Cys-Cys disulfide bonds. Thus, a substitution at a cysteine
residue results in a significant disruption of the structure of
the protein, with a relevant pathophysiologic impact on the
course of the disease [19]. Diagnostic delay was considerable
both in children and in adults, as reported also in patients
from the Eurofever registry [1]. More in detail, the diagnostic
delay was significantly more pronounced in the case of
childhood-onset and in patients carrying HP gene variants
than in adult-onset disease. Given the fact that the wide
majority of patients were adults at the time of data collection
(94%), with a median age of 44 years (range 9-77 years), we
assume that such discrepancy reflects the improving knowl-
edge of TRAPS in the last decades. Actually, pediatric-onset
patients manifested the disease far back in time compared
to adult-onset patients; thus, diagnostic capabilities, only
recently improved, have brought about a reduction in the
diagnostic delay especially among patients with adult-onset
disease.
With regard to the clinical spectrum of the disease, our
group previously observed that adult patients may both
exhibit a phenotype that mimics other autoinflammatory
disorders characterized by shorter inflammatory attacks, such
as familial Mediterranean fever, and present with oligosymp-
tomatic disease or atypical manifestations including isolated
myocarditis and pericarditis [20]. Consequently, adult-onset
TRAPS may frequently lead to misdiagnosis and improper
management [8, 18, 21]. Data from the present study confirm
the higher frequency of pericarditis in the context of adult-
onset disease and show a higher frequency of myalgia in this
subgroup as well. More in detail, in our cohort, eighteen
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Figure 5: Therapeutic regimens in TRAPS patients, according to age
at onset and genotype. Nonsteroidal anti-inflammatory drugs,
colchicine, and glucocorticoids shall be considered as monotherapy.
Only the first biologic line of treatment is shown in the charts. List
of abbreviations: NSAIDs: nonsteroidal anti-inflammatory drugs.
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of other serousal membranes in six cases. In this subgroup, the
mean age at onset was 29 years, and mild musculoskeletal
symptoms (arthralgia and myalgia) were reported more
frequently than other complaints. These findings are consistent
with data recently published from the Eurofever registry by ter
Haar et al. on patients with undefined AIDs [22]: arthralgia,
myalgia, and abdominal pain were often reported together with
pericarditis, suggesting that the presence of this combination
could be a clue for suspecting specific AIDs in patients with
otherwise idiopathic pericarditis. Indeed, the extension of
genetic analysis allowed the identification of the R92Q muta-
tion in two out of eight cases.
On the other hand, cervical lymphadenopathy, ocular
manifestations, and abdominal pain seem to be more fre-
quently complained by children according to current literature
[1, 8]. In particular, data from the Eurofever cohort showed
that abdominal pain at disease onset was similarly complained
by children and adults with pediatric-onset disease, while its
frequency was significantly lower in the adult-onset group
[1]. In line with these findings, abdominal pain was the only
clinical feature specifically associated with the pediatric age
at onset in our cohort. Similar data can be derived from differ-
ent case series reporting data from pediatric and adult-onset
TRAPS: Dodé et al., basing on 28 unrelated patients, reported
abdominal pain in 86.6% of pediatric-onset patients and 46.2%
of adult-onset cases [23]; Federici et al. published 19 TRAPS
patients, with abdominal involvement reported in 91.6% of
pediatric-onset disease [24]. On the contrary, in a large cohort
from NIH-Nottingham [5], the frequency of abdominal pain
was less remarkable between pediatric and adult-onset TRAPS
(92.3% versus 72.7%); nevertheless, the majority of patients
presenting with abdominal pain had HP variants, which are
per se strongly associated to the presence of abdominal pain
at onset, as also highlighted in the present study.
As expected, in the present study, patients with HP
mutations had more frequently a family history of recurrent
fever and higher levels of inflammatory markers with the
tendency to persist above the normal range also during
intercritic periods. Systemic amyloidosis at the time of
diagnosis affected only individuals carrying HP variants;
noteworthy, the presence of cysteine-mutations, abdominal
pain, or lymphadenopathy during attacks at disease onset
represented risk factors for the development of amyloidosis
and/or pathologic proteinuria. These findings agree with
Lane et al., who reported abdominal pain as the most repre-
sented symptom during fever attacks in 12 TRAPS patients
with AA amyloidosis [25]. Similarly, many studies confirm
the association between cysteine substitutions and higher risk
for amyloidosis [5, 26], while the detection of amyloidosis in
patients with LP variants is highly unusual [3, 15, 25]. Never-
theless, since kidney amyloidosis has also been reported in
R92Q and P46L patients, a regular screening of subclinical
inflammation through the dosage of SAA levels remains
recommended in patients carrying LP variants [7, 23, 27].
In this regard, the development of such unusual complication
may depend on the presence of other concomitant genetic
factors, such as different alleles of SAA1 gene. Furthermore,
the R92Q variant may act as an upregulator of the inflamma-
tory response in a nonspecific manner, thus contributing to
the likelihood of amyloidosis developing in certain patients
affected by multifactorial chronic inflammatory disorders
[28]. On this basis, the R92Q mutation is currently classified
as a variant of uncertain significance, and its pathogenic role
in causing TRAPS phenotypes is already controversial [29].
When considered pathogenic, it has been associated to a
protean clinical phenotype consisting in fever, abdominal
pain, arthralgia/arthritis, fatigue, myalgia, and less frequently
headache, odynophagia, skin rash, and chest pain with a
broad range of age at disease onset [3]. In line with previous
evidences, in our cohort of patients carrying R92Q variant,
disease onset was quite varied (ranging 1 to 54 years), with
frequent flares lasting 12 days on average characterized by
musculoskeletal symptoms, lymphadenopathy, skin rash,
and chest pain as most frequently complained symptoms.
Noteworthly, this subgroup of patients showed a slightly
different clinical picture when compared to other genotypes,
with a higher frequency of oral aphthosis and arthritis, lower
occurrence of abdominal pain, and lower ESR levels during
fever attacks. Patients with the R92Q variant were treated
with NSAIDs monotherapy more frequently than others;
nevertheless, more than half of them required biologic
therapy in addition to NSAIDs, glucocorticoids, and/or
colchicine along the course of the disease, disclosing a clinical
profile of intermediate severity overall. It has been previously
observed that patients carrying low-penetrance mutations
may exhibit a stubborn clinical course, needing chronic
administration of high doses of steroids and biologic thera-
pies to achieve good disease control [30]. In this regard, the
number of R92Q patients requiring cytokine blockers in
our cohort is surprisingly higher than previously reported
(2.9 to 22.2%) [2, 3, 7, 8, 15], although an omitted variable
bias cannot be excluded: actually, the recently increased
availability of biologic drugs and the greater familiarity of
clinicians with their employment has brought about a widen-
ing of their use over the last years for both therapeutic and
diagnostic purposes.
The recently developed and validated Eurofever classifica-
tion score for TRAPS comprises two different sets of criteria:
the first one is applicable to candidates carrying a confirming
genotype or a variant of uncertain significance; the second
one is designed to address appropriate patients towards genetic
testing, or towards further genetic studies (search for somatic
mosaicism); moreover, clinical criteria are formulated to classify
patients for research purposes even in those countries where
routine genetic testing is not possible. TRAPS classification
criteria involving both genetic and clinical items displayed a
sensitivity of 95% and a specificity of 99% when validated in
the Eurofever cohort [9]. In our cohort, this set of criteria
displayed a good performance (80% sensitivity overall) with a
trend towards a better sensitivity in the pediatric setting than
in the adult one, without reaching statistical significance. In
addition, they provided high utility in classifying patients with
HP variants (93.8% classified), while the sensitivity was lower
in the LP group (77.3%) when using the diagnosis given by
the treating physician as reference standard. These findings
may be due to the relevant number of patients with low-
penetrance mutations in our cohort, as negative or not confir-
matory genotype has been associated to a minor classification
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capability of the new classification score [9]. Anyway, the inclu-
sion of the genetic item (confirmatory and not confirmatory
genotypes) has led to a better capability of classifying patients
in all subgroups, especially among patients carrying LP variants.
On the other side, the version of clinical classification
criteria not including genotype (i.e., applicable prior to genetic
analysis) displayed a sensitivity of 87% and a specificity of 92%
when validated in the Eurofever cohort [9]. Nevertheless, in the
present study, on the basis of clinical manifestations at disease
onset, only 57.5% of patients resulted correctly classified as
TRAPS. The performance was particularly unsatisfactory in
the case of adult-onset disease (55.9% sensitivity) and among
patients carrying LP variants (50%). It is worthmentioning that
in the adult setting one out of five patients would have been
classified also as FMF, while in the pediatric setting one out
of five patients fulfilled MKD clinical classification criteria,
disclosing a specificity of 76% and 80% for FMF criteria in
adults and for MKD criteria in children, respectively. It is the
authors’ opinion that TRAPS clinical classification criteria
can be conveniently used to address appropriate patients
towards genetic testing or towards further in-depth genetic
analysis, but their employment for classifying patients in coun-
tries where routine genetic testing is not available should be fur-
ther assessed. Indeed, given the high phenotypic heterogeneity
of the syndrome and the frequent overlap between TRAPS
phenotype and other monogenic autoinflammatory diseases,
a definite classification should rely on both accurate working
clinical assessment and complementary genotype [31].
The multicentric retrospective nature of this study implies
some limitations. Firstly, clinical data about disease onset in
childhood were often recalled by adult patients; this retrospec-
tive collection might be determined some inaccuracy in some
useful information could have been missed. Moreover, the
majority of patients were Caucasian and our findings could
not be applied directly and uncritically to patients from other
geographic contexts. As regards the evaluation of classification
criteria, two main limitations have been identified: firstly, the
scores have been applied retrospectively on the basis of
collected data, and it is not excluded some misinterpretation
of symptoms; moreover, the absence of a control group has
not allowed us to derive the specificity of the different sets of
criteria. We outlined some clinical unmet needs in this field
of research, which would be fruitfully addressed in the future:
more detailed data about subsequent lines of biologic treat-
ment are missing in the present study, as well as clear outcome
measures when defining the response to treatments; moreover,
predictive factors of response to different cytokines inhibition
should be evaluated, with specific regard to genotypical asset;
moreover, an extensive analysis of data about long-term
follow-up of the pediatric-onset disease could allow the identi-
fication of different evolutive patterns and risk factors for
severe outcome.
In conclusion, the present study describes one of the
widest cohorts of TRAPS patients currently reported in the
literature. Some genetic and clinical features, including the
presence of mutations involving a cysteine residue, abdomi-
nal pain, and lymphadenopathy during attacks, significantly
correlate with long-term and severe TRAPS-related compli-
cations. Our data confirm the high phenotypic heterogeneity
of the disease, which seems more influenced by the pene-
trance of the mutation rather than by the age at onset itself,
although clear genotype-phenotype associations still need to
be defined.
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